Filing Flows › Comparisons › LFVN vs KROS
Lifevantage vs Keros Therapeutics: LFVN and KROS compared
Lifevantage is the larger company: $42.4M of revenue in its latest quarter (Q2 2026) against $40.0M for Keros Therapeutics (Q3 2026). Keros Therapeutics is growing faster (+183% against -23% a year earlier). Keros Therapeutics is more profitable, with an operating margin of 32.0% against 3.9%.
Where the money goes: LFVN and KROS
Lifevantage (LFVN) · Q2 2026
Lifevantage, Q2 2026: revenue $42.4M (-23% year over year), operating margin 3.9%, net earnings $1.3M, operating cash flow $4.8M. The chart follows the revenue to costs, profit and cash.
Keros Therapeutics (KROS) · Q3 2026
Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.
| Lifevantage (LFVN) | Keros Therapeutics (KROS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $42.4M | $40.0M |
| Revenue growth, Y/Y | -23% | +183% |
| Gross margin | 78.0% | — |
| Operating margin | 3.9% | 32.0% |
| Net earnings | $1.3M | $14.2M |
| Net margin | 3.0% | 35.4% |
| Operating cash flow | $4.8M | $3.4M |
| Free cash flow | $3.7M | $3.3M |
Where the revenue comes from
Lifevantage
- Protandim: $19.1M (45%)
- Life Vantage Product Line: $9.6M (23%)
- True Science Product Line: $9.0M (21%)
- AXIO Product Line: $4.2M (10%)
Questions
Which is bigger, Lifevantage or Keros Therapeutics?
Lifevantage is the larger company: $42.4M of revenue in its latest quarter (Q2 2026) against $40.0M for Keros Therapeutics (Q3 2026).
Is Lifevantage or Keros Therapeutics growing faster?
Keros Therapeutics is growing faster (+183% against -23% a year earlier).
Which is more profitable, Lifevantage or Keros Therapeutics?
Keros Therapeutics is more profitable, with an operating margin of 32.0% against 3.9%.
More: Lifevantage earnings · how Lifevantage makes money · Keros Therapeutics earnings · how Keros Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Aug 27, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.